socalTECH
DECEMBER 15, 2020
Los Angeles-based life sciences investor Westlake Village BioPartners announced today that it has raised two new venture capital funds, worth a total of $500M, for its investments in biotech companies. The venture investor says it has now raised more than $820M in total for its investments. READ MORE>>.
socalTECH
NOVEMBER 6, 2017
If successful, the IPO would join Newport Beach-based Veritone; Westlake Village-based Sienna Biopharmaceuticals; San Diego-based AmpliPhi Biosciences; San Diego-based Tocagen; Irvine-based Alteryx; San Diego-based AnapytsBio, and Venice-based Snap Inc on 2017's IPO list for the region.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
JANUARY 31, 2020
The Westlake Village, CA-based biotech sold about 9.4 Arcutis Biotherapeutics raised about $159 million from its IPO, offering 1.6 million more shares than anticipated and pricing at the high end of its planned range. million of its shares at $17 apiece. Arcutis (NASDAQ: ARQT ) shares began trading Friday.
socalTECH
NOVEMBER 16, 2012
18798% San Diego Pedro Lichtinger 22 Phone Power 7642% Winnetka Ari Ramezani 23 TeleSign Corporation Software 7534% Marina del Rey Steve Jillings 26 FastSpring 6742% Santa Barbara Dan Engel 30 Neurocrine Biosciences, Inc. 6225% San Diego Kevin C. 1548% San Diego Terrance H. 1548% San Diego Terrance H.
Xconomy
JANUARY 27, 2020
Two are clinical-stage biotechs: Cambridge, MA-based Black Diamond Therapeutics, which is looking to raise $151 million, and Westlake Village, CA-based Arcutis Biotherapeutics, which aims to add $125 million. Cancer drug developer Black Diamond filed IPO paperwork with regulators on Jan.
socalTECH
FEBRUARY 9, 2011
which has substantial operations in Westlake Village, Beverly Hills-based RealD , Monrovia-based Green Dot , and Woodland Hills-based ReachLocal. In fact, a recent study released by Ernst & Young found that there were eight companies in Southern California, out of 22 total in California, who were lined up for an IPO in Q4.
Xconomy
SEPTEMBER 5, 2018
Los Angeles has long been in San Francisco’s shadow when it comes to life sciences investment. Westlake Village BioPartners is launching today with $350 million in committed capital. But a new venture capital firm led by industry veterans is trying to cast the City of Angels in a new light.
Expert insights. Personalized for you.
113 
Let's personalize your content